China NMPA Drug Inspection - Heilongjiang Taxus chinensis Pharmaceutical Co., Ltd. - Compound Danshen Tablets

The National Medical Products Administration (NMPA) of China, formerly the State Food and Drug Administration, issued Announcement No. 54 of 2016 on March 14, 2016, detailing significant compliance issues found during national drug sampling inspections. These inspections identified 36 batches of substandard drugs from 29 pharmaceutical companies, including Suzhou Zhonghua Pharmaceutical Industry Co., Ltd. The problematic batches, predominantly manufactured between 2013 and 2015, exhibited various quality deficiencies. Key violations encompassed a range of critical quality control parameters. These included failures in dissolution rate, unacceptable levels of related substances, elevated bacterial counts, issues with solution clarity and color, presence of visible foreign matter, inadequate disintegration time, incorrect moisture content, and deviations in fill volume, weight variation, and content determination. Such widespread failures indicate systemic lapses in manufacturing quality and adherence to Good Manufacturing Practices. In response, the NMPA, through provincial food and drug administrations across 16 regions, mandated immediate actions. These included the suspension of production and sales for the affected drugs and an immediate recall of all substandard products. Furthermore, the implicated enterprises were required to conduct thorough investigations into the root causes of these deficiencies. Depending on the severity of the findings, legal proceedings were to be initiated. All companies were instructed to publicly disclose their investigation and handling results by May 31, 2016, and report them to the NMPA, ensuring accountability and corrective measures.